DCA Officials Seize ‘Diclojan Forte’ Tab For Misleading Claims

HYDERABAD: Officials of Drugs Control Administration, Telangana seized ‘DICLOJAN Forte Tablets (Diclofenac Sodium & Paracetamol Tablets),’ in Aiza Village, Jogulamba-Gadwal District, for making a misleading advertisement claiming it treats ‘fever.

In a statement here on Thursday, DCA Director-General VB Kamalasan Reddy said that the officials detected a medicine ‘DICLOJAN Forte Tablets’ circulating in the market with misleading claim on its label that it treats ‘fever’, which is a contravention of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. During the special raids conducted on 24th, and 25th April, officials from the Drugs Control Administration, Mahabubnagar Zone, detected ‘DICLOJAN Forte Tablets’. The said medicine was detected by DCA officials at a medical shop situated in Aiza Village, Aiza Mandal, Jogulamba-Gadwal District. Stocks were seized during the raid.

The advertisement of a medicine for the treatment of ‘fever’ in general is prohibited under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Mohd. Rafhi Shaik, Drugs Inspector, Gadwal and A.N. Kranthi Kumar, Drugs Inspector, Narayanpet are among the officers who carried out the raid. Further investigation shall be carried out and action shall be taken as per the law against all the offenders.

Persons who make misleading advertisements regarding drugs for treatment of certain diseases and disorders are punishable under Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, with imprisonment which may extend to six months, or with fine, or with both.

The public may report any complaints regarding illegal activities concerning medicines through the Drugs Control Administration, Telangana Toll-Free Number 1800-599-6969, which is operational from 10:30 am to 5:00 pm on all working days.

Related Posts

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?